Houston, Texas, United States
With over 20 years of work experience in the field of molecular diagnostics, I am passionate about delivering innovative, high-quality solutions that improve patient care and outcomes. At Revvity, I lead two specialized units that offers a range of clinical diagnostic testing services and cell-based molecular reference materials. I am driven by the mission of advancing precision medicine and personalized healthcare, and I bring diverse perspectives and experiences from working in different sectors, markets, and roles in the molecular diagnostics industry. In my current role, I leverage my expertise in next-generation sequencing, diagnostic, and life sciences to develop and implement strategic plans, partnerships, and projects that support the growth and expansion of Revvity's portfolio and capabilities. I am proud of the achievements and impact that my team and I have made in delivering cutting-edge diagnostics solutions that enhance accuracy, reliability, and efficiency of molecular testing and assay workflows.
Global certified (CLIA, CAP, ISO15189) OMICS services looking for collaborations with health care professional and pharmaceutical programs. Our capabilities includes development of new OMICS assays for diagnosis/clinical trials, supporting development of CDx. Our goal is to assist and accelerate the process of discovery to cure.
A specialized unit, offering a range of clinical diagnostic testing services to support HCP in patient care and offering a diverse range of multi-OMICS development, clinical trials and service for Biopharmaceutical companies.
ISO quality manufacturer of cell based molecular reference material (RefMat). Cell based RefMat is the closest mimic to patient material and is essential part of a robust molecular testing/assay workflow. Reach out and speak with us on how we can support your diagnostic testing program, pharmaceutical clinical trials, kit/reagent with the right molecular RefMat.
Lead global laboratory operations of PerkinElmer Genomics global lab sites. Designed, implemented & operate high-throughput COVID19 testing labs in UK & US with combined capacity to process up to 210k samples per day.
1st commercial team member at PerkinElmer Genomics. Led the global development of pharmaceutical, healthy testing and international diagnostic business.
ISO quality manufacturer of cell based molecular reference material (RefMat). Cell based RefMat is the closest mimic to patient material and is essential part of a robust molecular testing/assay workflow. Reach out and speak with us on how we can support your diagnostic testing program, pharmaceutical clinical trials, kit/reagent with the right molecular RefMat.
The Association of Genetic Technologists, Inc. (AGT), founded in 1975, is a non-profit professional organization established to promote cooperation and exchange of information among those engaged in classical cytogenetics, molecular and biochemical genetics and to stimulate interest in genetics as a career. The mission of the Association of Genetic Technologists is to provide to our membership, and the broader genetics community, quality services that enhance recognition of our profession and serve the public health and welfare. Don't wait, just us today! http://www.agt-info.org/Pages/joinagt.aspx
Business Development of Cytocell FISH probes*, CytoSure microarrays, and SureSeq NGS panels in North America. Identify new business opportunity and build customer relationships. Shape Cytocell FISH marketing and sales strategy for North America. Grew Cytocell North America FISH business by $3.3million (Jun 14 - Sept 16). Increased Cytocell distributor sales in Latin America by £82k (1366% increase) (Oct 15 - Mar 17). Increased CytoSure business in TX & LA by 102% in FY15 and 16% in FY16. *Main activity
Business development and account management of microarray and sequencing products and services for 16 central US states. Perform market analysis and help set sales strategy for North American molecular array sales. Help to shape molecular array marketing and sales strategy in FY14. Help develop marketing collateral to assist the sale of molecular arrays to worldwide customers. Grew CytoSure revenue in territory by 76%. Converted/acquired four new microarray accounts.